Soluble guanylyl cyclase-activated cyclic GMP-dependent protein kinase inhibits arterial smooth muscle cell migration independent of VASP-serine 239 phosphorylation

Cellular Signalling

Volumn 28, Issue 9, 2016, Pages 1364-1379

  Holt, Andrew W ^a   Martin, Danielle N ^a   Shaver, Patti R ^a   Adderley, Shaquria P ^a   Stone, Joshua D ^a   Joshi, Chintamani N ^a   Francisco, Jake T ^a   Lust, Robert M ^a   Weidner, Douglas A ^a   Shewchuk, Brian M ^a   Tulis, David A ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

BAY 60 2770; cGMP; Migration; PKG; Smooth muscle cell; VASP

Indexed keywords

BAY 60 2770; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENZYME ACTIVATOR; F ACTIN; G ACTIN; GUANYLATE CYCLASE; PLACEBO; SOLUBLE GUANYLYL CYCLASE; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN; 4-(((4-CARBOXYBUTYL) (2- (5-FLUORO-2-((4'-(TRIFLUOROMETHYL) BIPHENYL-4-YL)METHOXY)PHENYL)ETHYL) AMINO)METHYL)BENZOIC ACID; ACTIN; ACTIN BINDING PROTEIN; BENZOIC ACID DERIVATIVE; BIPHENYL DERIVATIVE; CELL ADHESION MOLECULE; FLUORINATED HYDROCARBON; MUTANT PROTEIN; PHOSPHOPROTEIN; PHOSPHOSERINE; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

ACTIN FILAMENT; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL SMOOTH MUSCLE CELL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; GENETIC TRANSFECTION; HEME OXIDATION; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; JUVENILE ANIMAL; MALE; MIGRATION INHIBITION; MOLECULAR DYNAMICS; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN PHOSPHORYLATION; RAT; SITE DIRECTED MUTAGENESIS; SMOOTH MUSCLE CELL; TIME SERIES ANALYSIS; VASCULAR REMODELING; WILD TYPE; ANIMAL; ARTERY; CELL MOTION; CYTOLOGY; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM; OXIDATION REDUCTION REACTION; PHOSPHORYLATION; REPRODUCIBILITY; SPRAGUE DAWLEY RAT;

ACTINS; ANIMALS; ARTERIES; BENZOATES; BIPHENYL COMPOUNDS; CELL ADHESION MOLECULES; CELL MOVEMENT; CYCLIC GMP-DEPENDENT PROTEIN KINASES; ENZYME ACTIVATION; HYDROCARBONS, FLUORINATED; MALE; MICROFILAMENT PROTEINS; MUTAGENESIS, SITE-DIRECTED; MUTANT PROTEINS; MYOCYTES, SMOOTH MUSCLE; OXIDATION-REDUCTION; PHOSPHOPROTEINS; PHOSPHORYLATION; PHOSPHOSERINE; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; SOLUBLE GUANYLYL CYCLASE; VASCULAR REMODELING;

EID: 84975886601     PISSN: 08986568     EISSN: 18733913     Source Type: Journal    
DOI: 10.1016/j.cellsig.2016.06.012     Document Type: Article

References (69)

1. [1] Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M., Das, S.R., Ferranti, S., Després, J.P., Fullerton, H.J., Howard, V.J., Huffman, M.D., Isasi, C.R., Jiménez, M.C., Judd, S.E., Kissela, B.M., Lichtman, J.H., Lisabeth, L.D., Liu, S., Mackey, R.H., Magid, D.J., McGuire, D.K., Mohler, E.R., Moy, C.S., Muntner, P., Mussolino, M.E., Nasir, K., Neumar, R.W., Nichol, G., Palaniappan, L., Pandey, D.K., Reeves, M.J., Rodriguez, C.J., Rosamond, W., Sorlie, P.D., Stein, J., Towfighi, A., Turan, T.N., Virani, S.S., Woo, D., Yeh, R.W., Turner, M.B., AHA statistical update: heart disease and stroke statistics 2016 update: a report from the American Heart Association. Circulation, 2015 published online before print December 16, 2015.
2. [2] Buys, E.S., Raher, M.J., Kirby, A., Mohd, S., Baron, D.M., Hayton, S.R., Tainsh, L.T., Sips, P.Y., Rauwerdink, K.M., Yan, Q., Tainsh, R.E., Shakartzi, H.R., Stevens, C., Decaluwe, K., Rodrigues-Machado, M.G., Malhotra, R., Van de Voorde, J., Wang, T., Brouckaert, P., Daly, M.J., Bloch, K.D., Genetic modifiers of hypertension in soluble guanylate cyclase alpha1-deficient mice. J. Clin. Invest. 122 (2012), 2316–2325.
3. [3] Chen, L., Daum, G., Fischer, J.W., Hawkins, S., Bochaton-Piallat, M.L., Gabbiani, G., Clowes, A.W., Loss of expression of the beta subunit of soluble guanylyl cyclase prevents nitric oxide-mediated inhibition of DNA synthesis in smooth muscle cells of old rats. Circ. Res. 86 (2000), 520–525.
4. [4] Ross, R., Glomset, J.A., Atherosclerosis and the arterial smooth muscle cell. Science 180 (1973), 1332–1339.
5. [5] Mendes-Silverio, C.B., Leiria, L.O.S., Morganti, R.P., Anhe, G.F., Marcondes, S., Monica, F.Z., De Nucci, G., Antunes, E., Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway. PLoS One, 7, 2012, e47223, 10.1371/journal.pone.0047223 First published November 8, 2012.
6. [6] Stasch, J.P., Hobbs, A.J., NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb. Exp. Pharmacol. 191 (2009), 277–308, 10.1007/978-3-540-68964-5_13.
7. [7] Bauters, C., Isner, J.M., The biology of restenosis. Prog. Cardiovasc. Dis. 40 (1997), 107–116.
8. [8] Andrew, P.J., Mayer, B., Enzymatic function of nitric oxide synthases. Cardiovasc. Res. 43 (1999), 521–531.
9. [9] Kubes, P., Suzuki, M., Granger, D.N., Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. 88 (1991), 4651–4655.
10. [10] Palmer, R.M.J., Ferige, A.G., Moncada, S., Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327 (1987), 524–526.
11. [11] Radomski, M.W., Palmer, R.M.J., Moncada, S., Modulation of platelet aggregation by an L-arginine-nitric oxide pathway. Trends Pharmacol. Sci. 12 (1991), 87–88.
12. [12] Scott-Burden, T., Vanhoutte, P.M., The endothelium as a regulator of vascular smooth muscle proliferation. Circulation 87 (1993), V51–V55.
13. [13] Brophy, C.M., Woodrum, D.A., Pollock, J., Dickinson, M., Komalavilas, P., Cornwell, T.L., Lincoln, T.M., cGMP-dependent protein kinase expression restores contractile function in cultured vascular smooth muscle cells. J. Vasc. Res. 39 (2002), 95–103.
14. [14] Fan, G.C., Kranias, E.G., Small heat shock protein 20 (HspB6) in cardiac hypertrophy and failure. J. Mol. Cell. Cardiol. 51 (2011), 574–577, 10.1016/j.yjmcc.2010.09.013 First published September 30, 2010.
15. [15] McLemore, E.C., Tessier, D.J., Thresher, J., Komalavilas, P., Brophy, C.M., Role of the small heat shock proteins in regulating vascular smooth muscle tone. JACS 201 (2005), 30–36.
16. [16] Feil, R., Lohmann, S.M., de Jonge, H., Walter, U., Hofmann, F., Cyclic GMP-dependent protein kinases and the cardiovascular system insights from genetically modified mice. Circ. Res. 93:10 (2003), 907–916 Nov 14.
17. [17] Woodrum, D., Pipkin, W., Tessier, D., Komalavilas, P., Brophy, C.M., Phosphorylation of the heat shock-related protein, HSP20, mediates cyclic nucleotide-dependent relaxation. J. Vasc. Surg. 37 (2003), 874–881.
18. [18] Aggarwal, S., Gross, C.M., Rafikov, R., Kumar, S., Fineman, J.R., Ludewig, B., Jonigk, D., Black, S.M., Nitration of tyrosine 247 inhibits protein kinase G-1α activity by attenuating cyclic guanosine monophosphate binding. J. Biol. Chem. 289 (2014), 7948–7961, 10.1074/jbc.M113.534313 (First published January 27, 2014).
19. [19] Dey, N.B., Lincoln, T.M., Possible involvement of Cyclic-GMP-dependent protein kinase on matrix metalloproteinase-2 expression in rat aortic smooth muscle cells. Mol. Cell. Biochem. 368 (2012), 27–35, 10.1007/s11010-012-1339-2 First published May 23, 2012.
20. 2 + and calcineurin by NO/PKG in proliferation of vascular smooth muscle cells. Acta Pharmacol. Sin. 26 (2005), 323–328.
21. [21] Yang, H.M., Kim, B.K., Kim, J.Y., Kwon, Y.W., Jin, S., Lee, J.E., Cho, H.J., Lee, H.Y., Kang, H.J., Oh, B.H., Park, Y.B., Kim, H.S., PPARγ modulates vascular smooth muscle cell phenotype via a protein kinase G-dependent pathway and reduces neointimal hyperplasia after vascular injury. Exp. Mol. Med., 45, 2013, e65.
22. [22] Erdmann, E., Semigran, M.J., Nieminen, M.S., Gheorghiade, M., Agrawal, R., Mitrovic, V., Mebazaa, A., Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur. Heart J. 34:1 (2013), 57–67.
23. [23] Doppler, H.R., Bastea, L.I., Lewis-Tuffin, L.J., Anastasiadis, P.Z., Storz, P., Protein kinase D1-mediated phosphorylations regulate vasodilator-stimulated phosphoprotein (VASP) localization and cell migration. J. Biol. Chem. 288 (2013), 24382–24393, 10.1074/jbc.M113.474676 First published July 11, 2013.
24. [24] Thomson, D.M., Ascione, M.P., Grange, J., Nelson, C., Hansen, M.D., Phosphorylation of VASP by AMPK alters actin binding and occurs at a novel site. Biochem. Biophys. Res. Commun. 414 (2011), 215–219, 10.1016/j.bbrc.2011.09.059 First published September 17, 2011.
25. [25] Trichet, L., Sykes, C., Plastino, J., Relaxing the actin cytoskeleton for adhesion and movement with Ena/VASP. J. Cell. Biol. 181 (2008), 19–25, 10.1083/jcb.200710168 First published March 31, 2008.
26. [26] Waldmann, R., Nieberding, M., Walter, U., Vasodilator-stimulated protein phosphorylation in platelets is mediated by cAMP-and cGMP-dependent protein kinases. Eur. J. Biochem. 167 (1987), 441–448.
27. [27] Cheng, A.M., Rizzo-DeLeon, N., Wilson, C.L., Lee, W.J., Tateya, S., Clowes, A.W., Schwartz, M.W., Kim, F., Vasodilator-stimulated phosphoprotein protects against vascular inflammation and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 307 (2014), E571–E579, 10.1152/ajpendo.00303.2014 First published August 12, 2014.
28. [28] Henes, J., Schmit, M.A., Morote-Garcia, J.C., Mirakaj, V., Kohler, D., Glover, L., Walter, U., Karthausen, J.M., Colgan, S.P., Rosenberger, P., Inflammation-associated repression of vasodilator-stimulated phosphoprotein (VASP) reduces alveolar-capillary barrier function during acute lung injury. FASEB J. 23 (2009), 4244–4255, 10.1096/fj.09-138693 First published August 18, 2009.
29. [29] Aizawa, T., Wei, H., Maino, J.M., Abe, J., Berk, B.C., Yan, C., Role of phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells. Circ. Res. 93 (2003), 406–413.
30. [30] Butt, E., Abel, K., Krieger, M., Palm, D., Hoppe, V., Hoppe, J., Walter, U., cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J. Biol. Chem. 269 (1994), 14509–14517.
31. [31] Chen, L., Daum, G., Chitaley, K., Coats, S.A., Bowen-Pope, D.F., Eigenthaler, M., Thumati, N.R., Walter, U., Clowes, A.W., Vasodilator-stimulated phosphoprotein regulates proliferation and growth inhibition by nitric oxide in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 24 (2004), 1403–1408.
32. [32] Joshi, C.N., Martin, D.N., Fox, J.C., Mendelev, N.N., Brown, T.A., Tulis, D.A., The soluble guanylate cyclase stimulator BAY 41-2272 inhibits vascular smooth muscle growth through the cAMP-dependent protein kinase and cGMP-dependent protein kinase pathways. J. Pharmacol. Exp. Thera. 339 (2011), 394–402, 10.1124/jpet.111.183400 First published August 8, 2011.
33. [33] Holt, A.W., Tulis, D.A., Experimental rat and mouse carotid artery surgery: injury & remodeling studies. ISRN Minim. Invasive. Surg., 2013, Article ID 167407, 10.1155/2013/167407 10 pages.
34. [34] Keswani, A.N., Peyton, K.J., Durante, W., Schafer, A.I., Tulis, D.A., The cyclic GMP modulators YC-1 and zaprinast reduce vessel remodeling through anti-proliferative and pro-apoptotic effects. J. Cardiovasc. Pharmacol. Ther. 14 (2009), 116–124, 10.1177/1074248409333266 (First published April 2, 2009).
35. [35] Stone, J.D., Narine, A., Shaver, P.R., Fox, J.C., Vuncannon, J.R., Tulis, D.A., AMP-activated protein kinase inhibits vascular smooth muscle cell proliferation and migration and vascular remodeling following injury. Am. J. Physiol. Heart. Circ. Physiol. 304 (2013), H369–H381, 10.1152/ajpheart.00446.2012 First published November 30, 2012.
36. [36] Tulis, D.A., Histological and morphometric analyses for rat carotid balloon injury model. Methods Mol. Med. 139 (2007), 31–66.
37. [37] Johnson, T.L., Tulis, D.A., Keeler, B.E., Virag, J.A., Lust, R.M., Clemens, S., The dopamine D3 receptor knockout mouse mimics aging-related changes in autonomic function and cardiac fibrosis. PloS One, 8, 2013, e74116, 10.1371/journal.pone.0074116 First published August 30, 2013.
38. [38] Adderley, S.P., Joshi, C.N., Martin, D.N., Mooney, S., Tulis, D.A., Multiple Kinase Involvement in the Regulation of Vascular Growth. Advance in Protein Kinases. Chapter 6. Da Silva Zavier, G., (eds.) InTech Open Access Publishers ISBN 978-953-51-0633-3, 2012, 131–150.
39. [39] Chen, H., Kovar, J., Sissons, S., Cox, K., Matter, W., Chadwell, F., Luan, P., Vlahos, C.J., Schutz-Geschwender, A., Olive, D.M., A cell-based immunocytochemical assay for monitoring kinase signaling pathways and drug efficacy. Anal. Biochem. 338 (2005), 136–142.
40. [40] Zamilpa, R., Ibarra, J., de Castro Brás, L.E., Ramirez, T.A., Nguyen, N., Halade, G.V., Zhang, J., Dai, Q., Dayah, T., Chiao, Y.A., Lowell, W., Ahuja, S.S., D'Armiento, J., Jin, Y.F., Lindsey, M.L., Transgenic overexpression of matrix metalloproteinase-9 in macrophages attenuates the inflammatory response and improves left ventricular function post-myocardial infarction. J. Mol. Cell. Cardiol. 53 (2012), 599–608, 10.1016/j.yjmcc.2012.07.017 First published August 3, 2012.
41. [41] Pankey, E.A., Bhartiya, M., Badejo, A.M. Jr., Haider, U., Stasch, J.P., Murthy, S.N., Nossaman, B.D., Kadowitz, P.J., Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme. Am. J. Physiol. Heart Circ. Physiol. 300 (2011), H792–H802, 10.1152/ajpheart.00953.2010 First Published January 7, 2011.
42. [42] Zhao, Y., Brandish, P.E., DiValentin, M., Schelvis, J.P., Babcock, G.T., Marletta, M.A., Inhibition of soluble guanylate cyclase by ODQ. Biochemistry 39:35 (2000), 10848–10854 Sep 5.
43. [43] Clowes, A.W., Reidy, M.A., Clowes, M.M., Mechanisms of stenosis after arterial injury. Lab. Investig. 49 (1983), 208–215.
44. [44] Tulis, D.A., Rat carotid artery balloon injury model. Methods Mol. Med. 139 (2007), 1–30.
45. [45] Sinnaeve, P., Chiche, J., Nong, Z., Varenne, O., Van Pelt, N., Gillijns, H., Janssens, S., Soluble guanylate cyclase α1 and β1 gene transfer increases NO responsiveness and reduces neointima formation after balloon injury in rats via antiproliferative and antimigratory effects. Circulation 88 (2001), 103–109.
46. [46] Sinnaeve, P., Chiche, J., Gillijns, H., Van Pelt, N., Wirthlin, D., Van de Werf, F., Janssens, S., Overexpression of a constitutively active protein kinase G mutant reduces neointima formation and in-stent restenosis. Circulation 105 (2002), 2911–2916.
47. [47] Wolfsgruber, W., Feil, S., Brummer, S., Kuppinger, O., Hofmann, F., Feil, R., A proatherogenic role for cGMP-dependent protein kinase in vascular smooth muscle cells. Proc. Natl. Acad. Sci. 100:23 (2003), 13519–13524 Nov 11.
48. [48] Tulis, D.A., Durante, W., Peyton, K.J., Chapman, G.B., Evans, A.J., Schafer, A.I., YC-1, a benzyl indazole derivative, stimulates vascular cGMP and inhibits neointima formation. Biochem. Biophys. Res. Commun. 279 (2000), 646–652.
49. [49] Louis, S.F., Zahradka, P., Vascular smooth muscle cell motility: from migration to invasion. Exp. Clin. Cardiol. 15 (2010), e75–e85.
50. [50] Tulis, D.A., Bohl Masters, K.S., Lipke, E.A., Schiesser, R.L., Evans, A.J., Peyton, K.J., Durante, W., West, J.L., Schafer, A.I., YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function. Biochem. Biophys. Res. Commun. 291 (2002), 1014–1021.
51. [51] Reinhard, M., Jouvenal, K., Tripier, D., Walter, U., Identification, purification, and characterization of a zyxin-related protein that binds the focal adhesion and microfilament protein VASP (vasodilator-stimulated phosphoprotein). Proc. Natl. Acad. Sci. 92 (1995), 7956–7960.
52. [52] Cramer, L.P., Briggs, L.J., Dawe, H.R., Use of fluorescently labelled deoxyribonuclease I to spatially measure G-actin levels in migrating and non-migrating cells. Cell Motil. Cytoskeleton 51 (2002), 27–38.
53. [53] Blume, C., Benz, P.M., Walter, U., Ha, J., Kemp, B.E., Renne, T., AMP-activated protein kinase impairs endothelial actin cytoskeleton assembly by phosphorylating vasodilator-stimulated phosphoprotein. J. Biol. Chem. 282 (2007), 4601–4612.
54. [54] Bear, J.E., Loureiro, J.J., Libova, I., Fässler, R., Wehland, J., Gertler, F.B., Negative regulation of fibroblast motility by Ena/VASP proteins. Cell 101 (2000), 717–728.
55. [55] Fu, M., Zhang, J., Tseng, Y.H., Cui, T., Zhu, X., Xiao, Y., Mou, Y., De Leon, H., Chang, M.M., Hamamori, Y., Kahn, C.R., Chen, Y.E., Rad GTPase attenuates vascular lesion formation by inhibition of vascular smooth muscle cell migration. Circulation 111 (2005), 1071–1077.
56. [56] Maciel, T.T., Melo, R.S., Schor, N., Campos, A.H., Gremlin promotes vascular smooth muscle cell proliferation and migration. J. Mol. Cell. Cardiol. 44 (2008), 370–379.
57. [57] Stone, J.D., Holt, A.W., Vuncannon, J.R., Brault, J.J., Tulis, D.A., AMP-activated protein kinase inhibits transforming growth factor-β-mediated vascular smooth muscle cell growth: implications for a Smad-3-dependent mechanism. Am. J. Physiol. Heart Circ. Physiol. 309 (2015), H1251–H1259, 10.1152/ajpheart.00846.2014.
58. [58] Mendelev, N.N., Williams, V.S., Tulis, D.A., Anti-growth properties of BAY 41-2272 in vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 53 (2009), 121–131.
59. [59] Defawe, O.D., Kim, S., Chen, L., Huang, D., Kenagy, R.D., Renné, T., Walter, U., Daum, G., Clowes, A.W., VASP phosphorylation at serine239 regulates the effects of NO on smooth muscle cell invasion and contraction of collagen. J. Cell. Physiol. 222:1 (2010), 230–237 Jan 1.
60. [60] Baens, M., Noels, H., Broeckx, V., Hagens, S., Fevery, S., Billiau, A.D., Vankelecom, H., Marynen, P., The dark side of EGFP: defective polyubiquitination. PloS one, 1(1), 2006, e54 Dec 20.
61. [61] Xie, Z.L., Shao, S.L., Lv, J.W., Wang, C.H., Yuan, C.Z., Zhang, W.W., Xu, X.J., Co-transfection and tandem transfection of HEK293A cells for overexpression and RNAi experiments. Cell Biol. Int. 35:3 (2011), 187–192 Mar 1.
62. [62] Dey, N.B., Foley, K.F., Lincoln, T.M., Dostmann, W.R., Inhibition of cGMP dependent protein kinase reverses phenotypic modulation of vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 45 (2005), 404–413, 10.1097/01.fjc.0000 157455.38068.12.
63. [63] Dostmann, W.R., Tegge, W., Frank, R., Nickl, C.K., Taylor, M.S., Brayden, J.E., Exploring the mechanisms of vascular smooth muscle tone with highly specific, membrane-permeable inhibitors of cyclic GMP-dependent protein kinase Iα. Pharmacol. Ther. 93 (2002), 203–215.
64. [64] Negash, S., Narasimhan, S.R., Zhou, W., Liu, J., Wei, F.L., Tian, J., Raj, J.U., Role of cGMP-dependent protein kinase in regulation of pulmonary vascular smooth muscle cell adhesion and migration: effect of hypoxia. Am. J. Physiol. Heart Circ. Physiol., 297(1), 2009, 1H304-12.
65. [65] Tulis, D.A., Novel therapies for cyclic GMP control of vascular smooth muscle growth. Am. J. Ther. 15 (2008), 551–564.
66. [66] Liu, X.M., Peyton, K.J., Mendelev, N.N., Wang, H., Tulis, D.A., Durante, W., YC-1 stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells. Mol. Pharmacol. 75 (2009), 208–217, 10.1124/mol.108.048314 First published October 15, 2008.
67. [67] Priviero, F., Webb, R.C., Heme-dependent and independent soluble guanylate cyclase activators and vasodilation. J. Cardiovas. Pharmacol. 56 (2010), 229–233.
68. [68] Knorr, A., Hirth-Dietrich, A., Alonso-Alija, C., Harter, M., Hahn, M., Keim, Y., Wunder, F., Stasch, J.P., Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. Arzneimittelforschung 58 (2008), 71–80.
69. [69] Tsai, E.J., Liu, Y., Koitabashi, N., Bedja, D., Danner, T., Jasmin, J.F., Lisanti, M.P., Friebe, A., Takimoto, E., Kass, D.A., Pressure-overload-induced subcellular relocalization/oxidation of soluble guanylyl cyclase in the heart modulates enzyme stimulation. Circ. Res. 110 (2012), 295–303, 10.1161/CIRCRESAHA.111.259242 First published November 17, 2011.